DMD Gene Therapy: Benefits in Young Patients
- New data suggests that delandistrogene moxeparvovec-rokl (Elevidys), a gene therapy developed by Sarepta Therapeutics, provides significant functional benefits for patients with Duchenne muscular dystrophy (DMD).
- the EMBARK study findings, presented at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, bolster the evidence supporting the use of delandistrogene moxeparvovec in...
- The analysis specifically looked at 14 patients, aged 8 to 9, who had initially received a placebo in part 1 of the EMBARK trial before crossing over to...
Groundbreaking results from the EMBARK study reveal that delandistrogene moxeparvovec gene therapy offers notable motor function improvements for young patients with Duchenne muscular dystrophy (DMD). Specifically,boys aged 8 and 9 showed meaningful advancements after treatment with this innovative DMD gene therapy. After one year, study participants experienced a 4.75-point difference in NSAA scores and notable improvements in time to rise and walk/run tests. This data lends further support to the clinical benefits of this therapy, providing new hope for those affected by this devastating disease. News Directory 3 is committed to keeping you informed on the latest advancements in healthcare. Discover what’s next in DMD treatment.
Gene Therapy Shows Promise for Duchenne Muscular Dystrophy
Updated June 13, 2025
New data suggests that delandistrogene moxeparvovec-rokl (Elevidys), a gene therapy developed by Sarepta Therapeutics, provides significant functional benefits for patients with Duchenne muscular dystrophy (DMD). The findings, stemming from part 2 of the EMBARK study, focused on boys aged 8 and 9.
the EMBARK study findings, presented at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, bolster the evidence supporting the use of delandistrogene moxeparvovec in treating DMD. Muscle weakness typically worsens during later childhood for those with DMD, with initial symptoms surfacing between ages 2 and 4.
The analysis specifically looked at 14 patients, aged 8 to 9, who had initially received a placebo in part 1 of the EMBARK trial before crossing over to receive the gene therapy. Results showed statistically significant differences compared to a matched external control group.
After one year of treatment, the study found a 4.75-point difference in North Star Ambulatory Assessment (NSAA) scores (P = .0026) between the groups. Researchers also noted a 6.87-second difference in time to rise from the floor (P = .0010) and a 4.76-second difference in the 10-meter walk/run test (P = .0097).
The data comes from an ongoing analysis of the EMBARK trial’s second part. The ASGCT presentation included two-year outcomes from 63 participants who received the